This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Soluble Beta-glucan (SBG) as Treatment for Diabetic Foot Ulcers

This study has been completed.
Information provided by:
Biotec Pharmacon ASA Identifier:
First received: February 29, 2008
Last updated: January 25, 2010
Last verified: January 2010
The purpose of this study is to determine whether the application of soluble beta-glucan (SBG) onto diabetic foot ulcers improves the healing of the ulcers.

Condition Intervention Phase
Chronic Diabetic Foot Ulcers Drug: Soluble beta-glucan (SBG) Drug: Placebo comparator Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomised, Double-blind, Placebo-controlled Study to Determine the Efficacy of Soluble Beta-1,3/1,6-glucan in Chronic Foot Ulcers in Diabetes

Resource links provided by NLM:

Further study details as provided by Biotec Pharmacon ASA:

Enrollment: 122
Study Start Date: March 2007
Study Completion Date: October 2009
Primary Completion Date: August 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Drug: Soluble beta-glucan (SBG)
Topical application of SBG to the wound, at least twice a week until complete healing or for 8 maximum weeks
Placebo Comparator: 2 Drug: Placebo comparator
Topical application of placebo to wound, at least twice a week until compleate healing or for maximum 8 weeks.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Type 1 or Type 2 diabetes mellitus
  • Age ≥ 18 years
  • One or more full-thickness ulcers at or below the level of the malleoli, which do not extend to tendon, joint, or bone
  • The ulcer (or index ulcer, if appropriate) must have been present for at least 4 weeks prior to Day 0 but not longer than 2 years
  • Ankle:brachial pressure index (ABPI) >0.7, or the presence of two palpable pulses on the affected foot
  • Ulcer area >25 mm2 but <500 mm2
  • Written informed consent

Exclusion Criteria:

  • Pregnancy, lactation or absence of adequate contraception for women with child bearing capacity
  • ABPI < 0.7
  • Serum albumin < 2.0 g/dL
  • Gangrene on any part of the foot with the study ulcer
  • Presence of signs of clinically significant foot infection on Day 0
  • Chronic renal failure with calculated GFR <30 ml/min
  • Surgical procedure (other than debridement) on the foot with the study ulcer in the 28 days prior to Day 0
  • HbA1c 12% or more
  • Current alcohol or drug abuse
  • Participation in other studies in the preceding 28 days
  • An ulcer on a foot affected by acute Charcot osteoarthropathy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00632008

United Kingdom
Belfast City Hospital
Belfast, United Kingdom, BT9 7AB
Royal Blackburn Hospital
Blackburn, United Kingdom, BB2 3LR
Royal Bournemouth Hospital
Bournemouth, United Kingdom, BH7 7DW
Southmead Hospital
Bristol, United Kingdom, BS10 5NB
NHS Greater Glasgow and Clyde Victoria
Glasgow, United Kingdom, G42 9TY
Leeds General Infirmary
Leeds, United Kingdom, LS1 3EX
Leicester General Hospital
Leicester, United Kingdom, LE5 4PW
North Manchester Hospital
Manchester, United Kingdom, M8 5RB
Newcastle General Hospital
Newcastle, United Kingdom, NE1 4LP
Northampton General Hospital
Northampton, United Kingdom, NN1 5BD
Nottingham City Hospital
Nottingham, United Kingdom, NG5 1PB
Sponsors and Collaborators
Biotec Pharmacon ASA
Principal Investigator: William Jeffcoate, MD, PhD Nottingham City Hospital
  More Information Identifier: NCT00632008     History of Changes
Other Study ID Numbers: SBG-1-12
Study First Received: February 29, 2008
Last Updated: January 25, 2010

Additional relevant MeSH terms:
Diabetic Foot
Foot Ulcer
Pathologic Processes
Diabetic Angiopathies
Vascular Diseases
Cardiovascular Diseases
Leg Ulcer
Skin Ulcer
Skin Diseases
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases
Diabetic Neuropathies
Foot Diseases processed this record on August 21, 2017